Clinical trials: Multiple Sclerosis
Multiple Sclerosis
Longitudinal Pharmacokinetic, Pharmacodynamic, Immunological, and Biochemical
This is an open-label study of patients with relapsing forms of Multiple Sclerosis designed to assess the longitudinal pharmacokinetic, pharmacodynamic, immunological, and biochemical sample collection with MRI and relapse…
- Trial name
- NCT01330498
- Where
- United States
- Volunteers
- 229 people
- Sponsor
- John F. Foley, MD
Tuberous Sclerosis Complex
Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy
This is a Phase 3, global, double-blind, randomized, placebo-controlled study of adjunctive GNX treatment in children and adults with TSC-related epilepsy.
- Trial name
- NCT05323734
- Testing
- Ganaxolone
- Where
- 63 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Marinus Pharmaceuticals
Relapsing Remitting Multiple Sclerosis
A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis
The goal of this clinical trial is to evaluate the safety and tolerability of terfenadine when added to standard first-line disease-modifying therapy in adults with multiple sclerosis.
- Trial name
- NCT07827716
- Testing
- Terfenadine, Standard First-line Disease-Modifying Therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chuan Qin
Multiple Sclerosis
Online Physical Activity Tracking in Patients With Multiple Sclerosis
This study aims to investigate the effects of regular remote monitoring of physical activity levels of individuals with multiple sclerosis on physical activity levels, psychological health, fatigue and quality of life.
- Trial name
- NCT06283563
- Testing
- Physical activity tracking, No physical activity tracking
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Inonu University
Multiple Sclerosis
Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063)
This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years.
- Trial name
- ENLIGHTEN (NCT04140305)
- Testing
- RPC-1063
- Where
- 61 sites in United States, Canada and 1 more
- Volunteers
- 188 people
- Sponsor
- Celgene
Multiple Sclerosis
Cognitive Improvement Through tDCS for Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease with around 200.000 patients in Germany. Besides physical symptoms, cognitive resources degrade over the years.
- Trial name
- MS-CICS (NCT04667221)
- Testing
- Active transcranial direct current stimulation
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University Medicine Greifswald
Shingles, Zoster
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.
- Trial name
- MSHINGVAX (NCT05596526)
- Testing
- recombinant zoster vaccine
- Where
- Switzerland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prof Patrice Lalive
Relapsing Multiple Sclerosis
A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability
A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability and efficacy of two daily doses of oral laquinimod (0.6mg or 1.2mg) in adjunct to glatiramer…
- Trial name
- NCT01404117
- Testing
- Laquinimod 0.6, Laquinimod 1.2
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Insomnia
Cognitive Behavioral Therapy for Insomnia to Address Insomnia Symptoms in People With Multiple Sclerosis
The purpose of this study is to learn if cognitive behavioral therapy for insomnia (CBT-I) will improve sleep quality, fatigue, and quality of life in individuals with multiple sclerosis (MS) with symptoms of insomnia.
- Trial name
- NCT03216889
- Testing
- Cognitive Behavioral Therapy for Insomnia, Control
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Kansas Medical Center
Rehabilitation, Multiple Sclerosis
Virtual Reality Approach in Multiple Sclerosis
The aim of our study is to investigate the effects of game-based virtual reality exercise added to conventional physiotherapy and rehabilitation program in patients with Multiple Sclerosis (MS).
- Trial name
- NCT04212689
- Testing
- Game Based Virtual Reality Exercises, Conventional Physiotherapy and Rehabilitation
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people
- Sponsor
- Marmara University
Multiple Sclerosis
Multiple Sclerosis Falls Insight Track
The purpose of this study is to develop an application: MS Falls Insight Track (MS FIT) which allows patients to log their falls and near falls, view their MS relevant data and responses to the clinic intake survey as well as…
- Trial name
- MS FIT (NCT05837949)
- Testing
- MS FIT: Falls Insight Track
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Francisco
Multiple Sclerosis
Testing the Efficacy of Self-Generation Treatment Protocol
Past research has shown that items self-generated by an individual, such as words or concepts, are remembered better than items that are simply read or heard.
- Trial name
- NCT02032589
- Testing
- Self-generation treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Kessler Foundation
Multiple Sclerosis, Progressive Multiple Sclerosis
Effect of Variance on Error Correction During Coupling
This study is a case-control study, involving persons with progressive multiple sclerosis and healthy controls. The study contains 1 descriptive and 3 experimental sessions.
- Trial name
- NCT04856384
- Testing
- synchronisation abilities
- Where
- 2 sites in Belgium
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Hasselt University
Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis
Cladribine Tablets as an Exit Therapy Strategy
The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational…
- Conditions
- Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Trial name
- CLADREXIT (NCT06887426)
- Testing
- Cladribine
- Where
- France
- Volunteers
- 450 people
- Sponsor
- University Hospital, Strasbourg, France
Central Neuropathic Pain, Multiple Sclerosis
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with multiple sclerosis.
- Trial name
- PRIME (NCT01324232)
- Testing
- AVP-923-45, AVP-923-30, AVP-923-20
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 209 people
- Sponsor
- Avanir Pharmaceuticals
Multiple Sclerosis, Relapsing-Remitting
An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS
The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on…
- Trial name
- ABOVE (NCT00206648)
- Testing
- Betaferon/Betaseron
- Where
- 53 sites in United States, Canada
- Volunteers
- 271 people
- Sponsor
- Bayer
Spasticity With Multiple Sclerosis
Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis
This study will be conducted to evaluate the effect of multiple doses of nabiximols compared with placebo on a clinical measure of velocity-dependent muscle tone in the lower limbs (Lower Limb Muscle Tone-6 [LLMT-6]) in…
- Trial name
- RELEASE MSS5 (NCT04984278)
- Testing
- Nabiximols
- Where
- 30 sites in United States, Czechia and 3 more
- Volunteers
- 56 people
- Sponsor
- Jazz Pharmaceuticals
MS CHRONIC PROGRESSIVE
Automated EDSS Score Calculation by Smartphone Application
The EDSS score is the reference tool for rating disability in patients with multiple sclerosis. It is used in both daily monitoring and clinical research studies.
- Trial name
- Easy EDSS (NCT03586635)
- Testing
- neurological exam
- Where
- France
- Volunteers
- 105 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Multiple Sclerosis, Relapsing-Remitting
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
Alemtuzumab is the active agent of a drug called Lemtrada®. In the European Union, Lemtrada® is approved for the treatment of a particular form of multiple sclerosis (the so called relapsing remitting form).
- Trial name
- ALAIN01 (NCT02419378)
- Testing
- Alemtuzumab
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Muenster
Multiple Sclerosis (MS), Unipolar Depression
Mood Disorders in Multiple Sclerosis Patients
This study investigates the frequency of unipolar and bipolar mood disorders in patients with multiple sclerosis. MS is a chronic condition that affects the central nervous system, and previous research suggests that mood…
- Conditions
- Multiple Sclerosis (MS), Unipolar Depression, Bipolar Disorder, Mood Disorders
- Trial name
- MSMD (NCT06652308)
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Islamic Azad University, Sanandaj